Actinium Pharmaceuticals (NYSE:ATNM) Receives “Overweight” Rating from Stephens

Stephens reissued their overweight rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report released on Tuesday,Benzinga reports. Stephens currently has a $5.00 price target on the stock.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.00 on Tuesday. Actinium Pharmaceuticals has a 1-year low of $0.95 and a 1-year high of $1.95. The company has a market capitalization of $31.05 million, a price-to-earnings ratio of -0.72 and a beta of -0.31. The business has a 50-day moving average of $1.14 and a 200-day moving average of $1.35.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Mayport LLC purchased a new stake in Actinium Pharmaceuticals during the 3rd quarter worth $35,000. AM Investment Strategies LLC purchased a new position in Actinium Pharmaceuticals in the 4th quarter valued at about $40,000. Qube Research & Technologies Ltd acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at about $70,000. Bailard Inc. purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter worth about $79,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter worth about $89,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.